Results 91 to 100 of about 936,037 (347)

Health disparities in chronic liver disease

Hepatology, EarlyView., 2022
Abstract The syndemic of hazardous alcohol consumption, opioid use, and obesity has led to important changes in liver disease epidemiology that have exacerbated health disparities. Health disparities occur when plausibly avoidable health differences are experienced by socially disadvantaged populations.
Ani Kardashian, Marina Serper, Norah Terrault, Lauren D. Nephew   +3 more
wiley   +1 more source

The regulatory role of IL-6R in hepatitis B-associated fibrosis and cirrhosis

Brazilian Journal of Medical and Biological Research, 2017
This study investigated the expression and regulation of IL-6R in hepatitis B-associated moderate hepatic fibrosis and cirrhosis. Liver tissues, peripheral blood monocytes (PBMs) and serum were collected from 26 hepatitis B patients with liver fibrosis ...
Y. Chen, S. Yang, Y. Peng, Z. Yang
doaj   +1 more source

Establishment of a hepatic cirrhosis and portal hypertension model by hepatic arterial perfusion with 80% alcohol.

World Journal of Gastroenterology, 2015
AIM To determine the feasibility and safety of establishing a porcine hepatic cirrhosis and portal hypertension model by hepatic arterial perfusion with 80% alcohol.
Lei Wang, F. He, Fuquan Liu, Z. Yue, Hongwei Zhao   +4 more
semanticscholar   +1 more source

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

Advanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang, Kejia Li, Ning Wang, Zhen Li, Zhiyong Zhang, Rocky S. Tuan, Yangzi Jiang   +6 more
wiley   +1 more source

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

Hepatology, EarlyView., 2022
Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres, Cristina Ortiz, Nadine Bachtler, Wenyi Gu, Leon D. Grünewald, Nico Kraus, Robert Schierwagen, Christoph Hieber, Caroline Meier, Olaf Tyc, Maximilian Joseph Brol, Frank Erhard Uschner, Bart Nijmeijer, Christoph Welsch, Marie‐Luise Berres, Carmen Garcia‐Ruiz, Jose Carlos Fernandez‐Checa, Christian Trautwein, Thomas J. Vogl, Stefan Zeuzem, Jonel Trebicka, Sabine Klein   +21 more
wiley   +1 more source

Double blind controlled trial of D-penicillamine in patients with primary biliary cirrhosis.

, 1985
One hundred and eighty nine patients with primary biliary cirrhosis were entered into a double blind, placebo controlled randomised trial starting in January 1978 to assess the therapeutic value of d-penicillamine 1200 mg daily.
Tygstrup, Niels, Williams, Roger, Rodés, J., Ranek, L., Neuberger, J., Christensen, E., Caballeria Rovira, Joan, Portmann, B.   +7 more
core   +1 more source

EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.

Journal of Hepatology, 2018
Summary The natural history of cirrhosis is characterised by an asymptomatic compensated phase followed by a decompensated phase, marked by the development of overt clinical signs, the most frequent of which are ascites, bleeding, encephalopathy, and ...
P. Angeli, M. Bernardi, C. Villanueva, C. Francoz, R. Mookerjee, J. Trebicka, A. Krag, W. Laleman, P. Ginés   +8 more
semanticscholar   +1 more source

Hepatoma‐Derived Growth Factor Coordinates STAT3 Pathway and Exosome‐Mediated Intrahepatic Crosstalk to Control Hepatic Steatosis and MASLD

Advanced Science, EarlyView.
Hepatic HDGF as a key mediator in coordinating hepatic steatosis and intrahepatic crosstalk in MASLD. Activation of HDGF facilitates its interaction with both STAT3 and S6K1, driving the S6K1‐dependent STAT3 phosphorylation and subsequently enhancing hepatic lipogenesis.
Jian Wen, Dong Ding, Zengpeng Zheng, Xufeng Chen, Wenjing Li, Jiaxin Shen, Zhiwei Huang, Peng Tan, Junjie Bai, Xia Fang, Baofang Xing, Puyuan Hu, Linghao Xu, Haokai Yu, Yixi Wang, Zongzhe Jiang, Yang Long, Tiejun Zhou, Mingxin Ye, Yu Jiang, Aoyuan Cui, Hong Li, Qiurong Ding, Yong Xu, Yu Li, Weitong Su, Feng Shen, Chenlin Gao, Wenguang Fu   +28 more
wiley   +1 more source

A shared mucosal gut microbiota signature in primary sclerosing cholangitis before and after liver transplantation

Hepatology, EarlyView., 2022
In this study of the gut mucosal microbiota in primary sclerosing cholangitis (PSC), we found consistent microbiota features associated with PSC and recurrent PSC, PSC with inflammatory bowel disease and a persistent gut dysbiosis after liver transplantation Abstract Background and Aims Several characteristic features of the fecal microbiota have been ...
Mikal Jacob Hole, Kristin Kaasen Jørgensen, Kristian Holm, Peder R. Braadland, Malin Holm Meyer‐Myklestad, Asle Wilhelm Medhus, Dag Henrik Reikvam, Alexandra Götz, Krzysztof Grzyb, Kirsten Muri Boberg, Tom Hemming Karlsen, Martin Kummen, Johannes R. Hov   +12 more
wiley   +1 more source

Hepatic Sarcoidosis Presenting as Portal Hypertension and Liver Cirrhosis: Case Report and Review of the Literature

Case Reports in Gastroenterology, 2012
Systemic sarcoidosis is a disease of unknown etiology, with the liver being the third most commonly affected organ. Most cases of hepatic sarcoidosis are not clinically apparent, but a few can progress to liver cirrhosis, portal hypertension and ...
Christopher B. Tan, Sadat Rashid, Dhyan Rajan, Wondwoosen Gebre, Paul Mustacchia   +4 more
doaj   +1 more source